Comparison of Frequency of Major Adverse Events in Patients With Atrial Fibrillation Receiving Bare-Metal Versus Drug-Eluting Stents in Their Coronary Arteries

      In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with drug-eluting stent (DES) implantation, the available evidence from clinical trial data are inconclusive. We evaluated the safety and efficacy of the use of DESs versus bare-metal stents (BMSs) in a consecutive real-world cohort of patients with AF. Of 8,962 unselected patients with AF seen in our institution from 2000 through 2010, 833 (9%) had undergone percutaneous coronary intervention with stent implantation. BMSs were used for 678 patients (81%) and DESs for 155 (19%). During follow-up (median 688 days, interquartile range 1,114), all bleeding episodes, thromboembolism, and major adverse cardiac events (MACEs; i.e., death, acute myocardial infarction, target lesion revascularization) were recorded. Incidence of MACEs was similar in the 2 groups as was incidence of all-cause mortality. Results remained similar even after adjustment for age and other confounding factors. Factors independently associated with an increased risk of MACEs were older age (hazard ratio 1.024, 95% confidence interval 1.004 to 1.044, p = 0.02), implantation of stent during acute ST-segment elevation myocardial infarction (hazard ratio 1.81, 95% confidence interval 1.10 to 2.99, p = 0.02), and stent diameter (hazard ratio 1.09, 95% confidence interval 1.01 to 1.18, p = 0.03). Implantation of DESs was not significantly associated with a higher risk of major bleeding and we observed a similar ratio of serious events at follow-up after DES compared to BMS implantation. In conclusion, in our cohort, systematic use of DESs does not seem to be justified in most patients with AF because it was not associated with any clear advantage compared to BMSs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Camm A.J.
        • Kirchhof P.
        • Lip G.Y.
        • Schotten U.
        • Savelieva I.
        • Ernst S.
        • Van Gelder I.C.
        • Al-Attar N.
        • Hindricks G.
        • Prendergast B.
        • Heidbuchel H.
        • Alfieri O.
        • Angelini A.
        • Atar D.
        • Colonna P.
        • De Caterina R.
        • De Sutter J.
        • Goette A.
        • Gorenek B.
        • Heldal M.
        • Hohloser S.H.
        • Kolh P.
        • Le Heuzey J.Y.
        • Ponikowski P.
        • Rutten F.H.
        Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology.
        Eur Heart J. 2010; 31: 2369-2429
        • Lip G.Y.
        • Nieuwlaat R.
        • Pisters R.
        • Lane D.A.
        • Crijns H.J.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
        Chest. 2010; 137: 263-272
        • Pisters R.
        • Lane D.A.
        • Nieuwlaat R.
        • de Vos C.B.
        • Crijns H.J.
        • Lip G.Y.
        A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.
        Chest. 2010; 138: 1093-1100
        • PRISM-PLUS Study Investigators
        Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
        N Engl J Med. 1998; 338: 1488-1497
        • Leon M.B.
        • Baim D.S.
        • Popma J.J.
        • Gordon P.C.
        • Cutlip D.E.
        • Ho K.K.
        • Giambartolomei A.
        • Diver D.J.
        • Lasorda D.M.
        • Williams D.O.
        • Pocock S.J.
        • Kuntz R.E.
        A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.
        N Engl J Med. 1998; 339: 1665-1671
        • Ruiz-Nodar J.M.
        • Marín F.
        • Sánchez-Payá J.
        • Hurtado J.A.
        • Valencia-Martín J.
        • Manzano-Fernández S.
        • Roldán V.
        • Pérez-Andreu V.
        • Sogorb F.
        • Valdés M.
        • Lip G.Y.
        Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation.
        Eur Heart J. 2009; 30: 932-939
        • Tu J.V.
        • Bowen J.
        • Chiu M.
        • Ko D.T.
        • Austin P.C.
        • He Y.
        • Hopkins R.
        • Tarride J.E.
        • Blackhouse G.
        • Lazzam C.
        • Cohen E.A.
        • Goeree R.
        Effectiveness and safety of drug-eluting stents in Ontario.
        N Engl J Med. 2007; 357: 1393-1402
        • McFadden E.P.
        • Stabile E.
        • Regar E.
        • Cheneau E.
        • Ong A.T.
        • Kinnaird T.
        • Suddath W.O.
        • Weissman N.J.
        • Torguson R.
        • Kent K.M.
        • Pichard A.D.
        • Satler L.F.
        • Waksman R.
        • Serruys P.W.
        Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.
        Lancet. 2004; 364: 1519-1521
        • Bavry A.A.
        • Kumbhani D.J.
        • Helton T.J.
        • Borek P.P.
        • Mood G.R.
        • Bhatt D.L.
        Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.
        Am J Med. 2006; 119: 1056-1061
        • Connolly S.
        • Pogue J.
        • Hart R.
        • Pfeffer M.
        • Hohnloser S.
        • Chrolavicius S.
        • Pfeffer M.
        • Hohnloser S.
        • Yusuf S.
        • The ACTIVE Investigators
        Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W).
        Lancet. 2006; 367: 1903-1912
        • Khurram Z.
        • Chou E.
        • Minutello R.
        • Bergman G.
        • Parikh M.
        • Naidu S.
        • Wong S.C.
        • Hong M.K.
        Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
        J Invasive Cardiol. 2006; 18: 162-164
        • Lip G.Y.
        • Huber K.
        • Andreotti F.
        • Arnesen H.
        • Airaksinen K.J.
        • Cuisset T.
        • Kirchhof P.
        • Marín F.
        • European Society of Cardiology Working Group on Thrombosis
        Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting.
        Thromb Haemost. 2010; 103: 13-28
        • Bavry A.A.
        • Bhatt D.L.
        Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis.
        Lancet. 2008; 371: 2134-2143
        • Dewilde W.
        • Berg J.T.
        Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST).
        Am Heart J. 2009; 158: 713-718
        • Wiviott S.D.
        • Braunwald E.
        • McCabe C.H.
        • Horvath I.
        • Keltai M.
        • Herrman J.P.
        • Van de
        • Werf F.
        • Downey W.E.
        • Scirica B.M.
        • Murphy S.A.
        • Antman E.M.
        • TRITON-TIMI 38 Investigators
        Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
        Lancet. 2008; 371: 1353-1363
        • Connolly S.J.
        • Ezekowitz M.D.
        • Yusuf S.
        • Eikelboom J.
        • Oldgren J.
        • Parekh A.
        • Pogue J.
        • Reilly P.A.
        • Themeles E.
        • Varrone J.
        • Wang S.
        • Alings M.
        • Xavier D.
        • Zhu J.
        • Diaz R.
        • Lewis B.S.
        • Darius H.
        • Diener H.C.
        • Joyner C.D.
        • Wallentin L.
        • RE-LY Steering Committee and Investigators
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151